The post All about AVAX’s latest buyback and what that means for its rally odds appeared on BitcoinEthereumNews.com. AVAX has returned to the spotlight after AVAXThe post All about AVAX’s latest buyback and what that means for its rally odds appeared on BitcoinEthereumNews.com. AVAX has returned to the spotlight after AVAX

All about AVAX’s latest buyback and what that means for its rally odds

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

AVAX has returned to the spotlight after AVAX One repurchased 2.4 million shares under its $40 million share buyback program. According to an updatet, the move signals confidence in the company’s long-term strategy.

CEO Jolie Kahn described the repurchase as a reflection of disciplined capital deployment. Such moves often strengthen investor sentiment. They also tend to put a lot of spotlight on the broader ecosystem.

Institutional demand begins to appear

In fact, at the time of writing, market data suggested that that larger investors have already started positioning themselves.

AVAX’s Open Interest has been rising slightly over the past 24 hours. Rising Open Interest often signals new capital entering the derivatives market. This is usually associated with growing institutional participation.

Such a signal becomes stronger when combined with whale activity.

Source: Coinglass

AVAX whales are also making moves

Avalanche network whales are also aligning to surging institutional purchases. According to the Spot Average Order Size data, token whales have been heavily investing on the dip.

Large investors are accumulating more orders across both Spot and Futures markets. This type of accumulation usually is evidence of strategic positioning, rather than short-term speculation.

Source: CryptoQuant

Buyers gain control of derivatives market

Another shift is happening in the derivatives market. Buyers have started to dominate Futures trading activity. This change in order flow could mean improving market confidence.

Historically, when buyers control derivatives markets, rallies often gain stronger support. The same projection could replicate itself on AVAX’s price action.

Source: CryptoQuant

Technical structure sends mixed signals

Finally, the technical outlook seemed to be presenting mixed signals at press time. On the daily chart, AVAX was continuing to trade above a wedge consolidation pattern. This meant that the broader structure still leaned bullish.

However, the altcoin was still trading below the exponential moving average (EMA) and the resistance zone at around the $10 psychological zone was still holding strong. This implied that bullish momentum had not fully returned yet.

If AVAX manages to reclaim the EMA, the rally could strengthen further.

For now, the market remains in a transition phase. However, rising Open Interest, whale accumulation and growing buyer dominance could allude to possible bullish continuation.

Source: TradingView


Final Summary

  • AVAX One repurchased 2.4M shares, boosting market confidence in Avalanche’s long-term projections.
  • Rising Open Interest and whale accumulation hinted at growing institutional positioning despite AVAX still trading below the EMA.
Next: CleanSpark and Bitcoin miners’ selling spree – Is the miner HODL era ending?

Source: https://ambcrypto.com/all-about-avaxs-latest-buyback-and-what-that-means-for-its-rally-odds/

Market Opportunity
Avalanche Logo
Avalanche Price(AVAX)
$9.02
$9.02$9.02
+0.45%
USD
Avalanche (AVAX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09